Navigation Links
Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
Date:9/8/2010

SAN FRANCISCO and ILLKIRCH, France, Sept. 8 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.  

JX-594, Jennerex's lead cancer biotherapeutic product, has shown anticancer activity and a well-tolerated safety profile in Phase 1 and Phase 2 clinical trials to date(1). Objective tumor response has been demonstrated in a variety of cancers including liver, colon, kidney, lung and melanoma.

Jennerex has awarded Transgene exclusive rights to develop and commercialize JX-594 in Europe, the CIS and the Middle East.  Jennerex and Transgene will co-develop JX-594 worldwide, with Transgene responsible for development costs and for clinical development in its licensed territories, pursuant to the JX-594 global development plan. Transgene is responsible for commercialization and has the right to manufacture JX-594 in the Transgene territory. As part of this agreement Transgene has made an upfront equity investment in Jennerex. Jennerex is further eligible to earn a total of up to $116 million in development and registration milestones as well as double digit royalties on a tiered structure. In addition, Jennerex has an option for co-promotion and profit-sharing in the five major European countries.

The development plan will focus initially on Hepatocellular Carcinoma (HCC), both in first line and in second line, and on colorectal cancer. Transgene and Jennerex intend to initiate a large randomized controlled phase 2b/3 clinical program in HCC patients. 
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
2. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
3. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
4. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
7. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
8. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
9. Sigma® Life Science Enters Genetically Modified Cell Market
10. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
11. Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced that ... at two upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO ... Second Annual Marcum LLP Microcap Conference on Thursday, May ... York City.  The presentation is scheduled to begin at ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Bed bugs already ... the pests is still ongoing, a report from kmov.com suggested ... for the bed bug treatment. Meanwhile, to be of help, ... from the costly bed bug exterminator service. , ... that AHA has so far spent $35,000 for ...
(Date:5/22/2013)... May 22, 2013 Oven Industries announces ... the integrated potentiometers or via a PC through the ... two and one half inches square can deliver up ... voltage switched, low noise solid state relay. Operator safety ... for the communication port and sensor input. Specifications: ...
(Date:5/22/2013)... 22, 2013   Oligomerix, Inc. , a ... modifying therapeutics for Alzheimer,s disease (AD) and related ... Series B financing, which includes both issuance of ... represent approximately $2.8M in new investments in the ... the raise. Funding from the ...
Breaking Biology Technology:Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2New AC Temperature Controller Announced by Oven Industries 2Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3
... highlights Volcano commitment to intravascular imaging ... opens up new clinical and research applications, ... Corporation (Nasdaq: VOLC ), a leading manufacturer ... and Optical,Coherence Tomography (OCT) products designed to enhance ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced it ... ended March 31,2008, on May 12, 2008 and host a ... will be Paul E. Freiman, President and Chief Executive,Officer, and ... for the call are as follows:, -- ...
... Technologies,Inc. (Amex: PTN ) will announce its third ... March 31, 2008 before the open of,the U.S. financial ... also conduct a teleconference and live audio webcast,hosted by ... which they,will discuss the results of operations in greater ...
Cached Biology Technology:Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 2Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 3Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 4Neurobiological Technologies Sets Date for Third Quarter Financial Results 2Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th 2
(Date:5/23/2013)... Given the implications for the overall health, development, ... a primary role in ensuring that all students ... minutes per day of vigorous or moderate-intensity physical ... of Medicine. Recent estimates suggest that only ... guideline for promoting better health and development. ...
(Date:5/23/2013)... (May 23, 2013) A new report from ... for helping pupils engage in at least 60 minutes ... day. , No more than half of American youth ... of vigorous or moderate intensity physical activity daily, according ... "Because children are in school for nearly half of ...
(Date:5/23/2013)... the natural history museums of the world are billions ... beetles to flowers, mushrooms and grasses, all stacked, stored ... rich and diverse collections could be critical to understanding ... of a growing human footprint if only the ... brought to life with the help of a team ...
Breaking Biology News(10 mins):Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Schools should provide students with daily physical activity, IOM recommends 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... low-sensitivity optical images of diseased tissues. So, four years ... Now, Wilson, a professor of biomedical engineering at ... cell in preclinical imaging studies. And he can pinpoint ... image. Called cryo-imaging, the system enables Wilson and ...
... Newark, NJ Current research suggests that the inflammatory molecule ... The related report by Alblowi et al, "High Levels ... Fracture Healing" appears in the October 2009 issue of the ... where the body either does not produce enough, or respond ...
... Ridgeland, Mississippi, a graduate student in biological sciences at ... Health (NIH) Graduate Research Fellowship for her study of ... a mosquito-borne disease that can cause seizures, coma, paralysis, ... a wildlife veterinarian, is pursuing her doctoral degree. The ...
Cached Biology News:Getting down to details 2Diabetes weakens your bones 2NIH fellowship recipient to study disease ecology 2